Opzelura

WILMINGTON, Del., July 29, 2026 Incyte announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the...

WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...